
This review will discuss how targeting these pathways can be a promising anticancer strategy. The exploitation of the DNA damage response and DNA repair proficiency of cancer cells is an important anticancer strategy. These same pathways also activate antimetabolites, an important group of chemotherapies that disrupt both nucleotide and DNA metabolism to induce DNA damage in cancer cells. Thus, dNTP metabolic enzymes can also be targeted to refine the use of these chemotherapeutics, many of which remain the standard of care in common cancers. This review article will discuss both these approaches exemplified by the enzymes MTH1, MTHFD2 and SAMHD1.
Like
Save
Share